Double-blind, Randomized, Placebo-controlled, Multi-center Trial, to Determine the Safety and Antiviral Effect of 14 Days of LCQ908 Monotherapy in Hepatitis C Infected Patients
Phase of Trial: Phase II
Latest Information Update: 07 May 2012
At a glance
- Drugs Pradigastat (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 07 May 2012 Actual patient number added 32 according to ClinicalTrials.gov.
- 07 May 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 07 May 2012 Actual initiation date changed from Jun 2011 to Jul 2011 as reported by ClinicalTrials.gov.